Fennec Pharmaceuticals Celebrates Successful Offering Closure
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) proudly announces the successful closing of its public offering of common shares. This substantial offering involved 5,366,667 shares, which includes the full exercise of the underwriters' option to purchase additional shares. At a public offering price of $7.50 per share, Fennec has successfully raised around $40.25 million in gross proceeds, before deducting underwriting discounts and other fees.
Strategic Utilization of Funds
The company plans to put the net proceeds from this offering to excellent use, primarily targeting the repayment and redemption of certain financial obligations. Furthermore, a portion of the funds will bolster Fennec's working capital and support general corporate initiatives, underpinning the company’s aim to innovate and expand its operations.
Collaboration with Leading Investment Firms
The offering enjoyed strong support from reputable financial partners. Piper Sandler & Co. and Craig-Hallum Capital Group LLC took on the role of joint book-running managers, with H.C. Wainwright & Co. serving as the lead manager and Stephens Inc. acting as a co-manager. Their expertise and commitment undoubtedly contributed to the offering's success.
Regulatory Compliance Ensured
This offering was carried out in compliance with regulations set forth by the Securities and Exchange Commission (SEC). Fennec filed a final prospectus supplement and an accompanying prospectus with the SEC, which are accessible on their official website. Moreover, interested parties can obtain these documents from Piper Sandler and Craig-Hallum directly.
A Commitment to Addressing Ototoxicity
Fennec specializes in mitigating the detrimental effects of platinum-based chemotherapy, specifically addressing ototoxicity in cancer patients. The company's focus lies in the commercialization of PEDMARK to help reduce the risks associated with this serious side effect. Having received FDA approval in September 2022, as well as regulatory nods from the European Commission and the U.K. in 2023, Fennec is well-positioned to make a significant impact in this space.
Exclusive Licensing Agreement
In an exciting move to expand its reach, Fennec entered into an exclusive agreement allowing Norgine Pharmaceuticals Ltd. to commercialize PEDMARQSI in Europe, the U.K., Australia, and New Zealand. This collaboration is a testament to Fennec's commitment to bringing its innovative solutions to markets where they are needed most.
Protecting Future Innovations
Fennec has strategically secured Orphan Drug Exclusivity for PEDMARK in the U.S. and received valuable Pediatric Use Marketing Authorization in Europe, ensuring an extended period of data protection and market exclusivity. With patents in place protecting PEDMARK until 2039, the company is committed to safeguarding its innovations as it continues to develop solutions for cancer patients.
Frequently Asked Questions
What is the main purpose of the stock offering completed by Fennec?
The stock offering primarily aims to repay certain debts and enhance working capital for ongoing corporate activities.
Who managed the offering for Fennec Pharmaceuticals?
Piper Sandler & Co., Craig-Hallum Capital Group LLC, H.C. Wainwright & Co., and Stephens Inc. played pivotal roles in managing the offering.
What is PEDMARK and its significance?
PEDMARK is Fennec's innovative solution aimed at reducing ototoxicity risks associated with chemotherapy, specifically for patients receiving cisplatin.
What regulatory approvals has Fennec received for its products?
Fennec has received FDA approval for PEDMARK in the U.S., alongside approvals in Europe and the U.K. for PEDMARQSI.
What are Fennec's future directions post-offering?
Post-offering, Fennec is focused on debt reduction, increasing its market presence, and continuing product development to support cancer patients.
